	US 11,911,346 B2
	Orally administrated therapeutic for treating mild cognitive impairment (MCI) and improving human cognitive function
Charles H. Marsland, Windermere, FL (US); and Stacey Bell, Reno, NV (US)
Assigned to Nutrient Survival LLC, Reno, NV (US)
Filed by BrainCare LLC, Reno, NV (US)
Filed on Aug. 27, 2021, as Appl. No. 17/459,889.
Prior Publication US 2023/0083707 A1, Mar. 16, 2023
Int. Cl. A61K 31/015 (2006.01); A61K 9/00 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/015 (2013.01) [A61K 9/0053 (2013.01); A61P 25/28 (2018.01)]

13 Claims

1. A therapeutic method of treating mild cognitive impairment and improving human cognitive function, comprising: daily, for a period of a plurality of weeks, orally administering a dose of at least about 90 mg Beta-Caryophyllene (BCP) to a human subject, whereas the BCP improves cognitive function as measured by the human subject's responses to one or more standard questionnaires.